Bridging cell and gene therapy process development with next generation automation

As cell and gene therapy processes turn to scalable manufacturing processes, many organizations are learning from previous bioprocess advances in automation and digitization. Adding these advances early in Process Development (PD) activities can provide speed and efficiency when entering technology transfer, clinical trials and commercial manufacturing. Knowledge and expertise from bioprocess learnings in eSOP’s, eBR’s, and facility dashboards can streamline processes, while reducing labor and risks when producing cellular therapies.

Speaker:
Shannon S Eaker, Cell Therapy Tech Sales Leader, Cytiva

Shannon received his PhD from the University of Tennessee, Knoxville in Biochemistry, Cellular and Molecular Biology. His expertise is around T-cell, HSC, and ES/iPSC cell biology, and has been with Cytiva for more than 7 years. He is a member of the International Society for Cell Therapy (ISCT) Process and Product Development (PPD) committee, and has authored numerous papers within the field of cell biology and manufacturing. He is currently the Technical Leader within Cytiva's Cell Therapy Enterprise Solutions group. Shannon lives with his wife and 2 children in Knoxville, TN.